ArticleOncology letters2026
Lymphocyte-to-C-reactive protein ratio as a clinically feasible nutrition-inflammation marker for predicting outcomes in patients with gastric cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains a major global health challenge, with substantial heterogeneity in clinical outcomes even among patients sharing the same American Joint Committee on Cancer stage. Inflammation-based biomarkers have attracted interest for their prognostic value; however, the significance of the lymphocyte-to-C-reactive protein ratio (LCR) in GC has not been systematically evaluated. A comprehensive literature search was performed in the PubMed, EMBASE and Cochrane Library databases in accordance with PRISMA guidelines. Studies assessing dichotomized LCR in relation to overall survival (OS) or disease-free survival (DFS) were eligible. Hazard ratios (HRs) were estimated using fixed- or random-effect models based on heterogeneity. Sensitivity and publication bias analyses were performed to evaluate the robustness of the findings. A total of 9 studies involving 4,429 patients were included in OS analysis. Results revealed that a low LCR was strongly associated with reduced survival [HR=2.24; 95% confidence interval (CI), 1.97-2.55]. A total of 5 studies involving 2,987 patients provided DFS data, revealing a similar association (HR=2.11; 95% CI, 1.78-2.51). Subgroup analysis indicated consistent prognostic effects across analytical methods, geographic regions, and treatment strategies. Sensitivity testing and funnel plots indicated stable results with no significant publication bias. In conclusion, a low LCR is a robust predictor of worse OS and DFS in GC and may complement existing staging systems to improve prognostic stratification. Standardized prospective studies are needed to validate its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.